Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
Conference call details: | |
Date: | |
Time: | |
URL to register phone: | |
Dial-in number: | (888) 880-3330 ( |
(+1) (646) 357-8766 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: | |
Date: | Available starting at |
Dial-in number: | (800) 770-2030 ( |
(+1) (609) 800-9909 (International) | |
Passcode: | 1309751# |
Webcast: | ir.novavax.com/events, until |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
844-668-2829
[email protected]
Media
844-264-8571
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2026-financial-results-on-may-6-2026-302757475.html
SOURCE Novavax, Inc.

